Quantcast

Industry news that matters to you.  Learn more

Archives for January 2014

Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application

As breast density becomes a more recognized risk factor for breast cancer, Royal Philips (NYSE: PHG, AEX: PHIA) recently announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Spectral Breast Density Measurement Application for its MicroDose SI full-field digital mammography (FFDM) system. The application is the first spectral Breast Density Measurement tool, meaning adipose (fat) and glandular tissue can be differentiated to accurately measure volumetric breast density.

OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker

Can-Fite BioPharma Ltd. (TASE: CFBI), (NYSE MKT: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced that the Company’s subsidiary, OphthaliX Inc. (OTCQB: OPLI), will conduct a retrospective analysis of its Phase III Dry Eye Syndrome study data to determine if there is a correlation between the A3 adenosine receptor (“A3AR”) biomarker and patients’ response to CF101. This analysis will be conducted as a result of recent positive data from the Phase IIb Rheumatoid Arthritis study where patients have been enrolled based on the presence of this biomarker.

Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network

A team led by the Accelerated Cure Project for Multiple Sclerosis (ACP) has been approved for a funding award by the Patient-Centered Outcomes Research Institute (PCORI) to create the Multiple Sclerosis Patient-Powered Research Network (MS-PPRN). The MS-PPRN is one of 29 health data networks that were approved for a total of $93.5 million from PCORI to form the PCORnet: the National Patient-Centered Clinical Research Network, a new national resource that aims to boost the efficiency of health research.

NanoString Technologies Announces Publication of Pivotal ABCSG-8 Study of the Prosigna Breast Cancer Assay

NanoString Technologies, Inc., (NASDAQ: NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced that Annals of Oncology, the journal of the European Society of Medical Oncology, has published a pivotal study validating the Prosigna™ Breast Cancer Prognostic Gene Signature Assay for predicting the risk of distant recurrence in postmenopausal women with Hormone Receptor-Positive (HR+) early-stage breast cancer. The study was based on an analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) trial and concluded that patients categorized by the Prosigna Assay as low risk are unlikely to benefit from additional chemotherapy. As a result of the authors independently replicating the results of the recently published TransATAC study, this study also showed that the Prosigna Assay has achieved Level 1 Evidence, the standard typically required for inclusion in cancer treatment guidelines.

HOPE Donates $50,000 to help St. Jude Children’s Research Hospital® Deliver on the Promise of Personalized Medicine

HOPE (Health Opportunity through Partnership in Education), together with Washington National Insurance Company, donates $50,000 to St. Jude Children’s Research Hospital® to support world-class pediatric cancer research.